Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | EIF4EBP1 | Q13541 | 10/20 | 0.33 |
| ▸ | PDE2A | O00408 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24002208 | 1.00 | GSK3B (0.34) | GSK3BCYP1A2CYP2D6P2RX7EIF4EBP1 | |
| SCHEMBL24001694 | 1.00 | GSK3B (0.34) | GSK3BCYP1A2CYP2D6P2RX7EIF4EBP1 | |
| SCHEMBL24002211 | 1.00 | GSK3B (0.34) | GSK3BCYP1A2CYP2D6P2RX7EIF4EBP1 | |
| SCHEMBL25453304 | 0.95 | GSK3B (0.34) | GSK3BCYP1A2CYP2D6P2RX7EIF4EBP1 | |
| SCHEMBL30402245 | 0.92 | P2RX7 (0.35) | GSK3BCYP1A2CYP2D6P2RX7EIF4EBP1 | |
| SCHEMBL24002032 | 0.92 | P2RX7 (0.35) | GSK3BCYP1A2CYP2D6P2RX7EIF4EBP1 | |
| SCHEMBL24002089 | 0.92 | P2RX7 (0.35) | GSK3BCYP1A2CYP2D6P2RX7EIF4EBP1 | |
| SCHEMBL24002010 | 0.92 | P2RX7 (0.34) | GSK3BCYP1A2CYP2D6P2RX7EIF4EBP1 | |
| SCHEMBL30293395 | 0.92 | P2RX7 (0.34) | GSK3BCYP1A2CYP2D6P2RX7EIF4EBP1 | |
| SCHEMBL24001853 | 0.91 | GSK3B (0.38) | GSK3BCYP1A2CYP2D6P2RX7PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4146220-B1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2026-02-18 | — | — | EP | claimed |
| US-20240190863-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-06-13 | — | — | US | claimed |
| EP-4146220-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Amgen Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| EP-4146220-B1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250388574-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12319691-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-12252489-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20240190863-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240124446-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11718617-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use | AMGEN INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230144581-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2023-05-11 | — | — | US | disclosed |
| EP-4146220-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Amgen Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252489-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | GSK3B 2996/4885CYP1A2 476/4885CYP2D6 1500/4885 |
| US-20240190863-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | GSK3B 2996/4885CYP1A2 476/4885CYP2D6 1500/4885 |
| US-12319691-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | GSK3B 3421/4885CYP1A2 417/4885CYP2D6 1342/4885 |
| US-20240124446-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | GSK3B 3421/4885CYP1A2 417/4885CYP2D6 1342/4885 |
| US-11718617-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use | MSR1, FPR2, CD14 | GSK3B 3411/4885CYP1A2 355/4885CYP2D6 1292/4885 |
| US-20230144581-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | GSK3B 3411/4885CYP1A2 355/4885CYP2D6 1292/4885 |
| US-20250388574-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FCER2, HAVCR2 | GSK3B 3178/4885CYP1A2 1623/4885CYP2D6 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.